https://www.selleckchem.com/GSK-3.html
[This corrects the article DOI 10.3892/ol.2019.11011.]. Copyright © Gao et al.Cisplatin-based systemic chemotherapy is the gold-standard approach for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (UC). However, the optimal number of cycles is still unclear. The current study retrospectively assessed the clinical outcome in patients who received gemcitabine and cisplatin (GC) chemotherapy as first-line treatment for metastatic urothelial cancer to clarify the timing of switching from GC therapy. A total of 61
Like
Comment
Share
